{"url_path":"/sec/cik-0001012477/8-k/2026-02-12/item-3-01","section_key":"item-3-01","section_title":"Item 3.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-02-12","source_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","accession_number":"0001104659-26-013880","cik":"0001012477","ticker":null,"issuer_name":"AVADEL PHARMACEUTICALS PLC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1012477/0001104659-26-013880-index.html","primary_entity_key":"0001012477","primary_entity_name":"AVADEL PHARMACEUTICALS PLC"},"word_count":155,"has_tables":true,"body_markdown":"**Item 3.01**\n**Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.**\n\n \n\nIn connection with the completion of the Acquisition, Avadel requested\nthat the Nasdaq Global Market (“Nasdaq”) (a) halt trading of the Avadel Shares effective as of 7:50 p.m. New York\nCity time on February 11, 2026 and (b) file with the Securities and Exchange Commission (the “SEC”) a Notification\nof Removal from Listing and/or Registration under Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange\nAct”), on Form 25 to delist the Avadel Shares. Upon effectiveness of such Form 25, Alkermes and Avadel intend to file\nwith the SEC a Certification and Notice of Termination of Registration on Form 15 under the Exchange Act, requesting that the Avadel\nShares be deregistered and that Avadel’s reporting obligations under Sections 13 and 15(d) of the Exchange Act be suspended\nwith respect to the Avadel Shares."}